Sellheyer Klaus, Nelson Paula, Kutzner Heinz, Patel Rajiv M
Department of Dermatology, Cleveland Clinic Foundation, Cleveland, OH, USA.
J Cutan Pathol. 2013 Apr;40(4):363-70. doi: 10.1111/cup.12085. Epub 2013 Feb 11.
Microcystic adnexal carcinoma (MAC), desmoplastic trichoepithelioma (DTE) and morpheaform basal cell carcinoma (BCC) frequently impose a considerable differential diagnostic challenge and immunohistochemistry is often used as a differentiating diagnostic adjunct.
Using standard immunohistochemical techniques, we examined 21 examples of DTE, 17 examples of morpheaform BCC and 10 examples of MAC for the expression of BerEP4, a marker of epithelial cells, and of three stem cell markers, pleckstrin homology-like domain, family A, member 1 (PHLDA1) [T cell death-associated gene 51 (TDAG51)], cytokeratin 15 (CK15) and cytokeratin (CK19).
All but one MAC was negative for BerEP4 and all morpheaform BCC expressed BerEP4. Sixteen out of 21 DTE were immunoreactive for BerEP4. All 21 DTE were PHLDA1 positive and all 17 morpheaform BCC were PHLDA1 negative. MAC showed a mixed staining pattern for PHLDA1. CK15 was expressed in 20/21 DTE, whereas the majority of cases of MAC and morpheaform BCC were CK15 negative. CK19 stained more MAC than DTE and morpheaform BCC.
BerEP4 differentiates between MAC and morpheaform BCC but not between MAC and DTE whereas PHLDA1 differentiates between DTE and morpheaform BCC but shows variable staining in MAC. CK15 and CK19 are helpful adjuncts in the differential diagnosis of sclerosing adnexal neoplasms but are second in line to BerEP4 and PHLDA1. We propose an algorithm for the immunohistochemical work-up of sclerosing adnexal neoplasms.
微囊性附属器癌(MAC)、促纤维增生性毛发上皮瘤(DTE)和硬斑病样基底细胞癌(BCC)常常带来相当大的鉴别诊断挑战,免疫组织化学常常被用作鉴别诊断辅助手段。
我们运用标准免疫组织化学技术,检测了21例DTE、17例硬斑病样BCC和10例MAC中上皮细胞标志物BerEP4以及三种干细胞标志物即 plekstrin 同源样结构域家族A成员1(PHLDA1)[T细胞死亡相关基因51(TDAG51)]、细胞角蛋白15(CK15)和细胞角蛋白(CK19)的表达情况。
除1例MAC外,其余所有MAC对BerEP4均呈阴性,所有硬斑病样BCC均表达BerEP4。21例DTE中有16例对BerEP4呈免疫反应性。所有21例DTE的PHLDA1均呈阳性,所有17例硬斑病样BCC的PHLDA1均呈阴性。MAC的PHLDA1呈现混合染色模式。20/21例DTE表达CK15,而大多数MAC和硬斑病样BCC病例的CK15呈阴性。CK19在MAC中的染色多于DTE和硬斑病样BCC。
BerEP4可区分MAC和硬斑病样BCC,但不能区分MAC和DTE;而PHLDA1可区分DTE和硬斑病样BCC,但在MAC中呈现可变染色。CK15和CK19有助于硬化性附属器肿瘤的鉴别诊断,但排在BerEP4和PHLDA1之后。我们提出了一种用于硬化性附属器肿瘤免疫组织化学检查的算法。